Quantum BioPharma Featured in CTV News Investigation on Stock Manipulation Allegations

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was the focus of CTV News' W5 program, which aired Part Three of an investigative series examining the company's allegations of stock spoofing. The allegations are tied to Quantum BioPharma's USD $700 million lawsuit against CIBC and RBC. The episodes detail rising market-manipulation cases in Canada and highlight the company's call for accountability in the financial sector.

CEO Zeeshan Saeed reaffirmed the company's commitment to defending shareholders and advancing research into multiple sclerosis. Co-Executive Chair Anthony Durkacz has offered up to USD $7 million for information leading to a final judgment or settlement in the related litigation. This substantial reward underscores the seriousness of the allegations and the company's determination to pursue legal recourse.

The broader implication of this news extends beyond Quantum BioPharma's specific case. The CTV W5 series positions it as a prominent example within a concerning trend of rising market-manipulation cases in Canada. For investors and market participants, this highlights ongoing vulnerabilities and regulatory challenges within the financial ecosystem. The company's public stance and legal action could encourage greater scrutiny of trading practices and potentially lead to more robust enforcement mechanisms to protect shareholder interests.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for treating challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of its lead compound, Lucid-MS. This patented new chemical entity has been shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

The company also retains significant interests in other ventures. It invented unbuzzd(TM) and spun out its over-the-counter version to Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025. The agreement includes royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses. The company also maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. The press release detailing the CTV News feature was disseminated by InvestorWire, a specialized communications platform that is one of 70+ brands within the Dynamic Brand Portfolio at IBN. For more information on InvestorWire, please visit https://www.InvestorWire.com. Full terms of use and disclaimers applicable to all content provided by InvestorWire are available at https://www.InvestorWire.com/Disclaimer.